IMPROVING BREAST CANCER OUTCOMES BY OVERCOMING RESISTANCE TO CDK4/6 INHIBITORS

Grant number: 1177357 | Funding period: 2020 - 2024

Active

Abstract

CDK4/6 inhibitors are a new class of cancer therapy used for the treatment of metastatic breast cancer. Although they are effective, cancers invariably develop resistance to these drugs over time and the reasons for this are unclear. Here, I will study mechanisms of CDK4/6 inhibitor resistance in the lab and will test several therapeutic approaches which have the potential to overcome it. If my results are promising, these new treatments could be readily taken into clinical trials.

Related publications (3)

University of Melbourne Researchers